Farmak Tafamidis Meglumine Farmak Tafamidis Meglumine

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Tafamidis

    Client Email Product

    Tafamidis

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Related ProductsRelated Products
    API SUPPLIERS
    API Suppliers

    API Suppliers

    24
    US DMFs Filed

    US DMFs Filed

    12
    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    1
    Other Suppliers

    Other Suppliers

    15
    API REF. PRICE (USD / KG)
    21,084

    API Market Place

    1
    INTERMEDIATES
    6
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    1
    Europe

    Europe

    0

    Canada

    Canada

    1
    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    2
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    547.00

    Annual Reports

    0

    FDF Market Place

    2
    EXCIPIENTS
    55
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    3

    USFDA Exclusivities

    2
    DIGITAL CONTENT

    Blog #PharmaFlow

    3

    News

    38
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    Full View ScreenFull Screen View
    Pfizer's tafamidis will hold its own against new meds: analysts
    Pfizer's tafamidis will hold its own against new meds: analysts

    https://www.fiercepharma.com/pharma/pfizer-tafamidis-hard-challenge-despite-potential-heart-disease-rivals-alnylam-bridgebio

    Angus Liu FIERCE PHARMA
    18 Sep 2023
    Share Share
    Pfizer, Scripps Sue to Block Copy of ‘Most Expensive’ Heart Drug
    Pfizer, Scripps Sue to Block Copy of ‘Most Expensive’ Heart Drug

    https://news.bloomberglaw.com/ip-law/pfizer-scripps-sue-to-block-copy-of-most-expensive-heart-drug

    BLOOMBERG LAW
    12 Aug 2023
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Tafamidis Capsules
    FDA Confirms Paragraph IV Patent Litigation for Tafamidis Capsules

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-tafamidis-capsules-21348.pdf

    FDA
    30 Jun 2023
    Share Share
    Pfizer prevails in proposed class action lawsuit over copays
    Pfizer prevails in proposed class action lawsuit over copays

    https://www.fiercepharma.com/pharma/pfizer-prevails-purchasers-class-action-lawsuit-over-patient-copay-assistance

    Kevin Dunleavy FIERCE PHARMA
    06 Apr 2023
    Share Share
    Pfizer’s VYNDAQEL/VYNDAMAX Reduces Risk of All-Cause Mortality by 41% in ATTR-CM
    Pfizer’s VYNDAQEL/VYNDAMAX Reduces Risk of All-Cause Mortality by 41% in ATTR-CM

    https://www.businesswire.com/news/home/20211220005606/en

    BUSINESSWIRE
    20 Dec 2021
    Share Share
    NICE says ‘no’ to Pfizer’s Vyndaqel for rare heart condition
    NICE says ‘no’ to Pfizer’s Vyndaqel for rare heart condition

    https://pharmaphorum.com/news/nice-says-no-to-pfizers-vyndaqel-for-rare-heart-condition/

    Richard Staines PHARMAPHORUM
    13 May 2021
    Share Share
    Pfizer Vyndaqel copay lawsuit could bring drug pricing shockwave
    Pfizer Vyndaqel copay lawsuit could bring drug pricing shockwave

    https://www.fiercepharma.com/pharma/fiercepharmapolitics-pfizer-vyndaqel-copay-lawsuit-could-bring-drug-pricing-shockwaves

    E.Sagonowsky FIERCE PHARMA
    13 Oct 2020
    Share Share
    Tafamidis After Therapy Delay Provides Long-Term Benefit for Patients
    Tafamidis After Therapy Delay Provides Long-Term Benefit for Patients

    https://www.firstwordpharma.com/node/1764207?tsid=1

    Ed Susman FIRSTWORLDPHARMA
    09 Oct 2020
    Share Share
    Regulator OKs Pfizer’s cardiomyopathy drug Vyndamax
    Regulator OKs Pfizer’s cardiomyopathy drug Vyndamax

    http://www.koreabiomed.com/news/articleView.html?idxno=9040

    S. Hyun-tai KOREABIOMEDICALREVIEW
    23 Aug 2020
    Share Share
    Vyndaqel, Ibrance boost Pfizer as it eyes COVID-19 shot launch
    Vyndaqel, Ibrance boost Pfizer as it eyes COVID-19 shot launch

    https://www.fiercepharma.com/pharma/vyndaqel-and-other-drugs-boost-pfizer-s-business-as-it-eyes-covid-19-vaccine-launch-year

    Angus Liu FIERCE PHARMA
    29 Jul 2020
    Share Share
    Vyndaqel® (active substances: tafamidis and tafamidis meglumine)
    Vyndaqel® (active substances: tafamidis and tafamidis meglumine)

    https://www.swissmedic.ch/swissmedic/en/home/about-us/publications/public-summary-swiss-par/public-summary-swiss-par-vyndaqel.html

    SWISSMEDIC
    22 Jun 2020
    Share Share
    Vyndaqel first treatment approved in Europe for ATTR-CM
    Vyndaqel first treatment approved in Europe for ATTR-CM

    http://www.pharmatimes.com/news/vyndaqel_first_treatment_approved_in_europe_for_attr-cm_1326476

    Anna Smith PHARMA TIMES
    19 Feb 2020
    Share Share
    European Commission Approves VYNDAQEL®, the First Treatment in the EU (ATTR-CM)
    European Commission Approves VYNDAQEL®, the First Treatment in the EU (ATTR-CM)

    https://press.pfizer.com/press-release/european-commission-approves-vyndaqel-first-treatment-eu-transthyretin-amyloid-cardiom

    PRESS RELEASE
    18 Feb 2020
    Share Share
    Pfizer's Vyndaqel off and running thanks to diagnosis push
    Pfizer's Vyndaqel off and running thanks to diagnosis push

    https://www.fiercepharma.com/pharma/pfizer-s-vyndaqel-off-and-running-9-diagnosis-rate-to-end-2019-execs

    E. Sagonowsky FIERCE PHARMA
    29 Jan 2020
    Share Share
    Pfizer's Vyndaqel off and running thanks to diagnosis push
    Pfizer's Vyndaqel off and running thanks to diagnosis push

    https://www.fiercepharma.com/pharma/pfizer-s-vyndaqel-off-and-running-9-diagnosis-rate-to-end-2019-execs

    Eric Sagonowsky FIERCE PHARMA
    29 Jan 2020
    Share Share
    Pfizer’s early Vyndaqel launch numbers are off the charts. Should Alnylam be worried?
    Pfizer’s early Vyndaqel launch numbers are off the charts. Should Alnylam be worried?

    https://www.fiercepharma.com/marketing/pfizer-s-vyndaqel-early-launch-numbers-are-off-charts-should-alnylam-be-worried

    Angus Liu FIERCE PHARMA
    02 Nov 2019
    Share Share
    Pfizer's Vyndaqel franchise, buoyed by diagnose, is poised for 'a decisive beat'
    Pfizer's Vyndaqel franchise, buoyed by diagnose, is poised for 'a decisive beat'

    https://www.fiercepharma.com/marketing/pfizer-s-vyndaqel-franchise-buoyed-by-diagnoses-poised-for-a-decisive-beat-analyst

    A. Liu FIERCE PHARMA
    19 Oct 2019
    Share Share
    AllianceRx Walgreens Prime Issues Updated List of New Specialty Drugs
    AllianceRx Walgreens Prime Issues Updated List of New Specialty Drugs

    https://www.prnewswire.com/news-releases/alliancerx-walgreens-prime-issues-updated-list-of-new-specialty-drugs-300903210.html

    PR NEWSWIRE
    16 Aug 2019
    Share Share
    Alnylam's Onpattro back in the game against Ionis, thanks to NICE U-turn
    Alnylam's Onpattro back in the game against Ionis, thanks to NICE U-turn

    https://www.fiercepharma.com/marketing/alnylam-s-onpattro-back-game-ionis-thanks-to-nice-u-turn?utm_source=internal&utm_medium=rss

    Angus Liu FIERCE PHARMA
    09 Jul 2019
    Share Share
    Pfizer’s tafamidis worth far more than $1.5B: analyst
    Pfizer’s tafamidis worth far more than $1.5B: analyst

    https://www.fiercepharma.com/marketing/pfizer-s-attr-drug-vyndaqel-vyndamax-asset-bigger-than-1-5b-says-analyst

    Angus Liu FIERCE PHARMA
    30 May 2019
    Share Share
    Pfizer's Vyndaqel, Vyndamax win US nod for rare disease
    Pfizer's Vyndaqel, Vyndamax win US nod for rare disease

    http://www.pharmatimes.com/news/pfizers_vyndaqel,_vyndamax_win_us_nod_for_rare_disease_1287186

    Anna Smith PHARMA TIMES
    08 May 2019
    Share Share
    Pfizer revs up for blockbuster fight as tafamidis nabs FDA nod
    Pfizer revs up for blockbuster fight as tafamidis nabs FDA nod

    https://www.fiercepharma.com/marketing/watch-out-alnylam-and-ionis-pfizer-s-blockbuster-hopeful-vyndaqel-back-fda-attr-nod

    Angus Liu FIERCE PHARMA
    07 May 2019
    Share Share
    Pfizer prospects for tafamidis market
    Pfizer prospects for tafamidis market

    https://www.biopharmadive.com/news/pfizer-tafamidis-launch-market-access-payer-pbm/553768/

    Jonathan Gardner BIOPHARMADIVE
    30 Apr 2019
    Share Share
    The 20 most expensive retail drugs in 2018
    The 20 most expensive retail drugs in 2018

    https://www.fiercepharma.com/pharma/top-20-most-expensive-drugs-2018-featuring-names-big-and-small

    Eric Sagonowsky FIERCE PHARMA
    29 Dec 2018
    Share Share
    Pfizer's Tafamidis Will Be Standard Of Care For A Not-So-Rare Disease
    Pfizer's Tafamidis Will Be Standard Of Care For A Not-So-Rare Disease

    https://seekingalpha.com/article/4202631-pfizers-tafamidis-will-standard-care-rare-disease

    Terry Chris SEEKING ALPHA
    29 Aug 2018
    Share Share
    Pfizer drug reduces mortality in patients with fatal heart disease
    Pfizer drug reduces mortality in patients with fatal heart disease

    https://pharmaphorum.com/news/tafamidis-reduces-mortality/

    Joy Persaud PHARMA PHORUM
    29 Aug 2018
    Share Share
    Pfizer impresses cardio crowd with tafamidis in ATTR-CM
    Pfizer impresses cardio crowd with tafamidis in ATTR-CM

    https://endpts.com/pfizer-wows-cardio-crowd-with-game-changing-mortality-and-hospitalization-rates-for-tafamidis-in-attr-cm/

    John Carroll ENDPTS
    28 Aug 2018
    Share Share
    Pfizer's tafamidis score still leaves 'door open' for Alnylam rival: analysts
    Pfizer's tafamidis score still leaves 'door open' for Alnylam rival: analysts

    https://www.fiercepharma.com/marketing/pfizer-s-tafamidis-score-still-leaves-door-open-for-alnylam-rival-analysts

    Carly Helfand FIERCE PHARMA
    28 Aug 2018
    Share Share
    Pfizer Achieves Success In Rare Heart Disease Study
    Pfizer Achieves Success In Rare Heart Disease Study

    https://seekingalpha.com/article/4202590-pfizer-achieves-success-rare-heart-disease-study

    Terry Chrisomalis SEEKING ALPHA
    28 Aug 2018
    Share Share
    Pfizer's drug for rare heart disease gets a boost
    Pfizer's drug for rare heart disease gets a boost

    https://www.businesstimes.com.sg/consumer/pfizers-drug-for-rare-heart-disease-gets-a-boost

    BUSINESS TIMES
    27 Aug 2018
    Share Share
    Pfizer eyes ATTR cardiomyopathy filing for tafamidis after acing phase 3 trial
    Pfizer eyes ATTR cardiomyopathy filing for tafamidis after acing phase 3 trial

    https://www.fiercebiotech.com/biotech/pfizer-eyes-attr-cardiomyopathy-filing-for-tafamidis-after-acing-phase-3-trial

    Phil Taylor FIERCE BIOTECH
    27 Aug 2018
    Share Share
    Xarelto flops, Pfizer’s tafamidis wins, Entresto’s early use and more
    Xarelto flops, Pfizer’s tafamidis wins, Entresto’s early use and more

    https://www.fiercepharma.com/marketing/esc-need-to-know-xarelto-flops-pfizer-s-tafamidis-win-entresto-s-early-use-and-more

    Angus Liu FIERCE PHARMA
    27 Aug 2018
    Share Share
    Pfizer gets breakthrough status from FDA for cardiomyopathy drug
    Pfizer gets breakthrough status from FDA for cardiomyopathy drug

    https://www.pfizer.com/news/press-release/press-release-detail/fda_grants_breakthrough_therapy_designation_for_tafamidis_for_the_treatment_of_patients_with_transthyretin_cardiomyopathy-0

    PRESS RELEASE
    27 May 2018
    Share Share
    Pfizer's tafamidis receives US FDA breakthrough therapy status
    Pfizer's tafamidis receives US FDA breakthrough therapy status

    http://www.pharmabiz.com/NewsDetails.aspx?aid=109088&sid=2

    PHARMABIZ
    24 May 2018
    Share Share
    Pfizer's ph 3 ATTR-ACT study of tafamidis to treat transthyretin cardiomyopathy
    Pfizer's ph 3 ATTR-ACT study of tafamidis to treat transthyretin cardiomyopathy

    http://www.pharmabiz.com/NewsDetails.aspx?aid=108090&sid=2

    PHARMABIZ
    30 Mar 2018
    Share Share
    Pfizer's rare heart disease drug succeeded in a late-stage study
    Pfizer's rare heart disease drug succeeded in a late-stage study

    https://www.cnbc.com/2018/03/29/pfizers-rare-heart-disease-drug-succeeded-in-a-late-stage-study.html

    CNBC
    29 Mar 2018
    Share Share
    Chi-Med Highlights Phase III Fruquintinib Data in Oral Presentation at ASCO
    Chi-Med Highlights Phase III Fruquintinib Data in Oral Presentation at ASCO

    http://www.businesswire.com/news/home/20170605005897/en/Chi-Med-Highlights-Phase-III-Fruquintinib-Data-Oral/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==

    BUSINESSWIRE
    06 Jun 2017
    Share Share
    Pfizer Receives FDA Fast Track Designation for Tafamidis for Transthyretin
    Pfizer Receives FDA Fast Track Designation for Tafamidis for Transthyretin

    http://www.businesswire.com/news/home/20170606005572/en/Pfizer-Receives-FDA-Fast-Track-Designation-Tafamidis/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==

    BUSINESSWIRE
    06 Jun 2017
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    Inke Tafamidis

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Nuray Tafamidis

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search